ASH 2024 | Full-body MRI and PET/CT in the diagnosis and treatment of multiple myeloma

In last year’s we have seen a revolution in multiple myeloma. I think that now according to all the drugs and combinations that have been registered in last years, we should start to be ambitious also with the diagnostic tools that we are going to use in our patients. Particularly in our institution we are going to personalize the treatment according to first with imaging improving and which we combine full body MRI with PET-CT. We have presented here at San Diego, ASH 2024, our preliminary data with the combination full body, three Tesla, MRI with PET-CT and we have seen that in about 20-25 percent of the patients this combination can change totally the outcome. This is incredible because we can anticipate the treatment in smoldering myeloma, pre-detect relapse, so anticipate the treatment relapse in refractory setting, or start the treatment before newly diagnosed in multiple myeloma. I think that this data should be increased in number but are particularly enthusiastic for the next future of this clinical trial that we are going to continue. Together with this we have presented also radiopsy poster in which we shown the imaging patterns that this patient have shown inside the whole body MRI and there are particularly interesting figures that have been analyzed by our colleagues of health physics with which we have seen that with accurate pre-evaluation inside a correct imaging analysis we can pre-detect the symptomatic status in terms of newly diagnosed in terms of relapsed and refractory. And I think that this is going to be integrated with the molecular evaluation that we are performing. We use a SCI-92 panel in our patient and we have compared this with the FISH, with the standard cytogenetic, and we have seen that with the SCI-92, with an evaluation in gene expression profiling of 92 genes, the profiling is more accurate. The long-term evaluation is particularly interesting and this is the basis to develop biomarkers for our patients, biomarkers of response to different drug and combination and maybe next future combining all these methods first to understand which drug or which combination for which patients but moreover hopefully to detect a new prognostic score. Hoping that this will be the basis for a target driven approach, I think that personalized medicine should not be the future but should be the present and this is my dream together with the dreams that according to all the novelties that we are seeing we will be able to cure multiple myeloma and this is the best wish that I give to our patients their caregivers and to all myeloma researchers.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.